SEC Filing Summary: Revelation Biosciences, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Revelation Biosciences, Inc. on October 6, 2022. The company is a Delaware corporation headquartered in San Diego, California, and is classified as an emerging growth company. The filing primarily serves to disclose a corporate presentation delivered by CEO James Rolke at the Roth Inaugural Healthcare Opportunities Conference in New York City on the same date.
Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is a disclosure of a presentation event rather than a financial statement filing.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing references a corporate presentation (Exhibit 99.1) but explicitly states that the information contained therein is not treated as "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Guidance, Outlook, and Risks
While the filing references a corporate presentation that likely contains management commentary and outlook, the text of the 8-K itself does not detail specific guidance, risks, contingencies, or unusual items. Investors must refer to the attached Exhibit 99.1 for the content of the presentation, noting that such content carries different legal liability standards than filed financial data.
Key Facts for Investor Verification
- The filing discloses a corporate presentation given on October 6, 2022, but does not include the presentation's financial details within the 8-K text.
- Information in the referenced presentation is not considered "filed" under Section 18 of the Exchange Act.
- The company trades on NASDAQ under symbols REVBU (Units), REVB (Common Stock), and REVBW (Warrants).
- No specific financial metrics or operational updates are provided in this specific document.